Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bismuth subcitrate potassium (marketed under the brand name Bismanthin by Aani Darman) is a colloidal bismuth salt used primarily in combination with antibiotics (such as metronidazole and tetracycline) and a proton pump inhibitor (such as omeprazole) for the eradication of *Helicobacter pylori* infections and the treatment of peptic ulcer disease. It acts locally in the stomach by forming a protective, acid-resistant coating over the ulcerated mucosa, stimulating mucosal prostaglandin and bicarbonate secretion, and exerting direct bactericidal effects against *H. pylori*. It disrupts bacterial cell walls and inhibits key bacterial enzymes, including the ATP-dependent Clp protease ATP-binding subunit ClpX.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bismuth subcitrate potassium.